文献速递消化道肿瘤放疗放疗物理与技术

ERI引导的自适应剂量提升在局部晚期直肠癌中的前瞻性THUNDER-2试验结果

Early regression index-guided adaptive dose escalation in locally advanced rectal cancer: results of the prospective THUNDER-2 trial.
PubMed 文献 · Radiother Oncol · 2026-08-04

非应答者完全缓解率从历史预期的约3%提升至21.9%,毒性可接受,ERI是唯一与完全缓解显著相关的变量。

要点

  • ERI>13.1的预测非应答者接受自适应boost至60.1 Gy,完全缓解率达21.9%。
  • 应答者无全直肠系膜切除生存显著优于非应答者(38.7% vs 8.3%,HR 2.35,p=0.004)。
  • ERI是单变量和多变量分析中唯一与完全缓解显著相关的变量(校正OR 0.912,p=0.028)。

核心结论

  • ERI引导的MRI自适应剂量提升在预测非应答者中可行,完全缓解率高于历史预期,支持个体化治疗强化和保器官策略。

研究设计与样本

  • 于模拟定位与第10次治疗分次之间计算ERI,ERI≤13.1继续标准放疗,ERI>13.1接受在线自适应放疗boost至60.1 Gy。
  • 完全缓解定义为病理完全缓解或2年持续临床完全缓解,临床完全缓解者考虑非手术治疗并密切随访。

主要发现

  • 自适应剂量提升使非应答者完全缓解率从历史预期约3%提高至21.9%,毒性可接受。
  • 应答者无全直肠系膜切除生存显著高于非应答者(38.7% vs 8.3%;HR 2.35,95%CI 1.29-4.26;p=0.004)。
  • 非应答者中出现2例局部再生长,均成功挽救。
  • ERI是单变量和多变量分析中唯一与完全缓解显著相关的变量(校正OR 0.912,95%CI 0.840-0.990;p=0.028)。

关键数值与推荐

  • ERI阈值13.1:ERI≤13.1继续标准放疗,ERI>13.1接受自适应boost至60.1 Gy。
  • 完全缓解定义为病理完全缓解或2年持续临床完全缓解。

临床怎么用

  • 可在新辅助放化疗第10次分次前后计算ERI,识别预测非应答者并考虑MRI引导在线自适应剂量提升至60.1 Gy。
  • 对达到临床完全缓解者可按试验方案考虑非手术治疗并密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Complete response (CR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) is associated with improved outcomes and may enable organ-preserving strategies. The Early Regression Index (ERI) is an imaging biomarker developed to predict treatment response. THUNDER-2 trial investigated ERI-guided magnetic resonance imaging (MRI)-based adaptive dose escalation to improve CR rates in predicted non-responders. MATERIALS AND METHODS: Patients with LARC underwent MRI-guided nCRT with concurrent capecitabine or 5-fluorouracil. ERI was calculated between simulation and the 10th treatment fraction. Patients with ERI ≤ 13.1 continued standard radiotherapy, whereas those with ERI > 13.1 received an adaptive boost to 60.1 Gy using online adaptive radiotherapy. CR was defined as pathological complete response (pCR) or sustained clinical complete response (cCR) at 2 years. Patients with cCR were considered for non-operative management with intensive follow-up. RESULTS: Sixty-two patients were enrolled (48.4% responders, 51.6% non-responders). Adaptive dose escalation increased the CR rate in non-responders from the historically expected value of approximately 3% to 21.9%, while maintaining acceptable toxicity. Responders achieved significantly higher TME (total mesorectal excision)-free survival than non-responders (38.7% vs 8.3%; hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.29-4.26; p = 0.004). Two local regrowths occurred among non-responders and were successfully salvaged. ERI was the only variable significantly associated with CR in both univariate and multivariable analyses (adjusted odds ratio (OR) 0.912, 95% CI 0.840-0.990; p = 0.028). CONCLUSION: ERI-guided MRI-based adaptive dose escalation was feasible and associated with higher-than-expected CR rates in predicted non-responders, supporting personalized treatment intensification and organ-preservation strategies in LARC (THUNDER-2; NCT04815694).

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chiloiro G, Romano A, Boldrini L, et al. Early regression index-guided adaptive dose escalation in locally advanced rectal cancer: results of the prospective THUNDER-2 trial. Radiother Oncol. 2026. PMID: 42551632. doi:10.1016/j.radonc.2026.111719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。